JOHN STOSSEL: Woke ESG Culture Going Down In Flames During Trump Era

Companies Reviewing GLP-1 Coverage Should Also Review Transgender Healthcare Coverage 

According to reports earlier this month, Starbucks is ending GLP-1 coverage for its employees. Under its new healthcare plan, Starbucks will no longer cover prescription drugs used for weight loss, but it will continue to cover comprehensive transgender healthcare interventions, including reconstructive surgical procedures and puberty blockers, for covered dependents. Employers are pulling back on GLP-1 coverage largely for the same reason they are reconsidering other benefits: to adjust to rising healthcare costs. RxBenefits reports that GLP-1 drugs cost roughly $1,000–$1,500 per month, while SHRM estimates employers often shoulder 70–100% of prescription drug costs.  With GLP-1s now accounting for around 20% of prescription drug spending and the number of users accelerating, employers face a limited set of choices: tighten eligibility requirements, shift more of the cost to employees or customers, or eliminate coverage altogether.  If companies can reasonably reconsider GLP-1 coverage because of cost, uncertain return on investment, and broader questions over what an employer-sponsored health plan should cover, why should other expensive medical benefits, such as transgender medical interventions, be exempt from similar scrutiny?  According to February 2026 data from the Human Rights Campaign, more than 550 major companies, including Starbucks, offer comprehensive transgender healthcare benefits to employees and covered dependents. While …

The Course of ESG Investing

As ESG-related practices have come under increasing scrutiny in the United States and abroad, newly released data paints a clearer picture of the current state of ESG investing. Two realities stand out: Perhaps the clearest example of the ESG exodus lies in the investor movement away from ESG mutual funds. These funds have bled $65.7 billion since 2022, roughly 20% of their average assets. Additionally, new fund launches have collapsed from 116 in 2021 to just nine last year, and BlackRock has slashed its support for ESG shareholder proposals from 40% in 2021 to less than 2% (7/358) in 2025. Even the 2026 proxy season backs this up: no ESG proposal won majority support. But this does not mean ESG will disappear. Many of its most committed proponents are doubling down, pursuing ESG through less visible channels, or lying low until a more favorable political and regulatory environment emerges. For example, CalPERS has all but dropped the word “ESG,” now calling it “sustainability integration,” while still on track to nearly double its climate-related holdings to $100 billion by 2030. BlackRock’s Larry Fink stopped using the term too, calling it “weaponized.” The rhetoric has cooled, but the strategy has not. Investors have …

BlackRock and other firms ‘weaponized’ retirement portfolios to push ESG, watchdog says

Behind Colgate’s Pro-DEI Vote: BlackRock, Blue-State Pension Funds, and a Rigged System

Opinion: After Years of Weaponizing Shareholder Voting, Will the Big Three Escape Accountability?

NYC Pension Funds Say BlackRock, Fidelity not Aligned with Climate Expectations